2026-01-27 - Analysis Report
**Company Overview:**
UnitedHealth Group is a leading healthcare services and insurance company in the United States.

**Return Rate Comparison:**
| Ticker | Cumulative Return | Last Day Return |
| --- | --- | --- |
| UNH (Review Stock) | 39.50% | N/A |
| VOO (Comparison Stock, S&P 500) | 127.58% | N/A |
| Divergence (Current) | -85.10 | N/A |
| Divergence (Relative) | 14.00% | N/A |

Analysis:
The cumulative return of the review stock (UNH) is significantly lower than that of the comparison stock (VOO). However, the divergence has decreased from its maximum to its current position, indicating a possible trend reversal.

**Alpha, Beta Analysis:**
| Period | CAGR | MDD | Alpha | Beta | Market Cap |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 47.0% | 18.6% | 38.0% | 0.9 | $225.7B |
| 2017-2019 | 40.0% | 19.3% | 15.0% | 0.9 | $266.3B |
| 2018-2020 | 26.0% | 34.8% | 2.0% | 1.1 | $317.7B |
| 2019-2021 | 82.0% | 34.8% | 17.0% | 1.1 | $454.9B |
| 2020-2022 | 82.0% | 34.8% | 78.0% | 0.9 | $480.3B |
| 2021-2023 | 46.0% | 15.8% | 28.0% | 0.5 | $476.9B |
| 2022-2024 | -23.0% | 21.6% | -52.0% | 0.4 | $458.2B |
| 2023-2025 | -89.0% | 59.3% | -164.0% | 0.3 | $299.0B |

Analysis:
The Alpha values for some periods are significantly high, indicating high returns in those periods. However, the Beta values show volatility in the stock, which may be a concern for investors.

**Recent Stock Price Fluctuations:**
| SMA | Value |
| --- | --- |
| 5-day | $349.71 |
| 20-day | $340.54 |
| 60-day | $332.64 |

Analysis:
The 5-day, 20-day, and 60-day moving averages are trending downward, indicating a possible downtrend in the stock.

**RSI, PPO Index Indicators:**
| Indicator | Value |
| --- | --- |
| Market Risk Indicator (MRI) | 0.70 |
| RSI | 56.40 |
| PPO | 0.45 |

Analysis:
The Market Risk Indicator is in the medium-risk category. The RSI is around neutral, and the PPO is slightly positive, indicating a potential buy signal.

**Hybrid Signal:**
Buy (Cash 0%)

Analysis:
The hybrid signal is indicating a buy signal with no cash allocation.

**Recent Relative Divergence Change:**
+3.60 (Improving)

Analysis:
The recent relative divergence change is improving, indicating a potential uptrend in the stock.

**Delta_Previous_Relative_Divergence:**
No data provided.

**Expected_Return (%):**
188.70%

Analysis:
The long-term expected return is around 188.70%.

**Sharp Rebound/Sharp Decline:**
The fluctuation issue is reflected as a sharp decline in the stock price.

**Recent News & Significant Events:**
1. Health insurers tumble after Trump administration proposes keeping Medicare Advantage rates flat next year - CNBC (news.google.com)
2. Is UnitedHealth Group (UNH) a 'Buy' Ahead of Its Upcoming Earnings Announcement? - Zacks Investment Research (news.google.com)
3. UnitedHealth Earnings All About the Outlook - Yahoo Finance (news.google.com)
4. Looking for Exposure to UnitedHealth Stock (UNH) ahead of Q4 Earnings? Hereâ€™s How to Buy Without the Risk - TipRanks (news.google.com)
5. SA analyst upgrades/downgrades: GM, UBER, UNH, NVS - Seeking Alpha (news.google.com)
6. U.S. politician makes super suspicious $500k healthcare stock trade - Finbold (news.google.com)

**Analyst Opinions:**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.93 (~Buy)
- Opinions: 26
- Target Price (avg/high/low): 393.77 / 444.00 / 280.00

Analysis:
The analyst consensus is indicating a strong buy signal with a target price of around $393.77.

**Recent Earnings Analysis:**
| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-10-28 | 2.59 | $113.16 B |
| 2025-08-11 | 3.76 | $111.62 B |
| 2025-05-07 | 6.9 | $109.58 B |
| 2024-11-04 | 6.56 | $100.82 B |
| 2025-10-28 | 6.56 | $100.82 B |

Analysis:
The earnings per share and revenue are showing a general trend of increasing from 2024 to 2025.

**Revenue and Profitability:**
| Quarter | Revenue | Profit Margin |
| --- | --- | --- |
| 2025-09-30 | $113.16B | 18.24% |
| 2025-06-30 | $111.62B | 17.93% |
| 2025-03-31 | $109.58B | 21.70% |
| 2024-12-31 | $100.81B | 21.14% |
| 2024-09-30 | $100.82B | 22.84% |

Analysis:
The revenue and profit margin are generally increasing from 2024 to 2025.

**Capital and Profitability:**
| Quarter | Equity | ROE |
| --- | --- | --- |
| 2025-09-30 | $95.79B | 2.45% |
| 2025-06-30 | $94.72B | 3.60% |
| 2025-03-31 | $95.04B | 6.62% |
| 2024-12-31 | $92.66B | 5.98% |
| 2024-09-30 | $94.53B | 6.41% |

Analysis:
The equity and return on equity are generally increasing from 2024 to 2025.

**Comprehensive Analysis:**
The stock is showing a mix of positive and negative indicators, including a buy signal from the hybrid signal, improving relative divergence change, and increasing revenue and profit margin. However, the stock price is trending downward, and the PPO is slightly positive but low. The Market Risk Indicator is in the medium-risk category. Overall, the comprehensive analysis suggests a possible buy signal with caution.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.